Human umbilical cord matrix-derived stem cells expressing interferon-β gene significantly attenuate bronchioloalveolar carcinoma xenografts in SCID mice

Lung Cancer

Volumn 70, Issue 1, 2010, Pages 28-36

  Matsuzuka, Takaya ^a   Rachakatla, Raja Shekar ^a   Doi, Chiyo ^a   Maurya, Dharmendra Kumar ^a   Ohta, Naomi ^a   Kawabata, Atsushi ^a   Pyle, Marla M ^a   Pickel, Lara ^a   Reischman, Jennifer ^a   Marini, Frank ^b   Troyer, Deryl ^a   Tamura, Masaaki ^a  

^a KANSAS STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bronchioloalveolar carcinoma; H358 cells; Interferon ; SCID mice; Stem cell therapy; SW1573 cells; Umbilical cord matrix derived stem cells; Xenografts

Indexed keywords

BETA INTERFERON; BETA INTERFERON HUMAN UMBILICAL CORD MATRIX MESENCHYMAL STEM CELL; CELL THERAPY AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; COCULTURE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; LUNG ALVEOLUS CELL CARCINOMA; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; STEM CELL; TREATMENT OUTCOME; TUMOR XENOGRAFT; UMBILICAL CORD;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ANIMALS; CELL DEATH; CELL GROWTH PROCESSES; CORD BLOOD STEM CELL TRANSPLANTATION; CULTURE MEDIA, CONDITIONED; FEMALE; GENE EXPRESSION; HUMANS; INTERFERON-BETA; LUNG NEOPLASMS; MESENCHYMAL STEM CELLS; MICE; MICE, SCID; TRANSFECTION; UMBILICAL CORD; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956187466     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.01.003     Document Type: Article

References (38)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009.
2. Wong V.L., Rieman D.J., Aronson L., Dalton B.J., Greig R., Anzano M.A. Growth-inhibitory activity of interferon-beta against human colorectal carcinoma cell lines. Int J Cancer 1989, 43:526-530.
3. Zhang H., Koty P.P., Mayotte J., Levitt M.L. Induction of multiple programmed cell death pathways by IFN-beta in human non-small-cell lung cancer cell lines. Exp Cell Res 1999, 247:133-141.
4. Chawla-Sarkar M., Leaman D.W., Borden E.C. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res 2001, 7:1821-1831.
5. Xu L., Xie K., Fidler I.J. Therapy of human ovarian cancer by transfection with the murine interferon beta gene: role of macrophage-inducible nitric oxide synthase. Hum Gene Ther 1998, 9:2699-2708.
6. Izawa J.I., Sweeney P., Perrotte P., Kedar D., Dong Z., Slaton J.W., et al. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis. Clin Cancer Res 2002, 8:1258-1270.
7. Nakahara N., Pollack I.F., Storkus W.J., Wakabayashi T., Yoshida J., Okada H. Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells. Cancer Gene Ther 2003, 10:549-558.
8. Natsume A., Mizuno M., Ryuke Y., Yoshida J. Antitumor effect and cellular immunity activation by murine interferon-beta gene transfer against intracerebral glioma in mouse. Gene Ther 1999, 6:1626-1633.
9. Wilderman M.J., Sun J., Jassar A.S., Kapoor V., Khan M., Vachani A., et al. Intrapulmonary IFN-beta gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung. Cancer Res 2005, 65:8379-8387.
10. Lang F.F., Bruner J.M., Fuller G.N., Aldape K., Prados M.D., Chang S., et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003, 21:2508-2518.
11. Studeny M., Marini F.C., Dembinski J.L., Zompetta C., Cabreira-Hansen M., Bekele B.N., et al. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 2004, 96:1593-1603.
12. Studeny M., Marini F.C., Champlin R.E., Zompetta C., Fidler I.J., Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002, 62:3603-3608.
13. Nakamizo A., Marini F., Amano T., Khan A., Studeny M., Gumin J., et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005, 65:3307-3318.
14. Rachakatla R.S., Marini F., Weiss M.L., Tamura M., Troyer D. Development of human umbilical cord matrix stem cell-based gene therapy for experimental lung tumors. Cancer Gene Ther 2007, 14:828-835.
15. Reed J.C., Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood 2005, 106:408-418.
16. Reed J.C. Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Pract Oncol 2006, 3:388-398.
17. Shinoura N., Yoshida Y., Sadata A., Hanada K.I., Yamamoto S., Kirino T., et al. Apoptosis by retrovirus- and adenovirus-mediated gene transfer of Fas ligand to glioma cells: implications for gene therapy. Hum Gene Ther 1998, 9:1983-1993.
18. Shimizu M., Takeda Y., Yagita H., Yoshimoto T., Matsuzawa A. Antitumor activity exhibited by Fas ligand (CD95L) overexpressed on lymphoid cells against Fas+ tumor cells. Cancer Immunol Immunother 1998, 47:143-148.
19. Arai H., Gordon D., Nabel E.G., Nabel G.J. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci USA 1997, 94:13862-13867.
20. Gomez-Navarro J., Arafat W., Xiang J. Gene therapy for carcinoma of the breast: Pro-apoptotic gene therapy. Breast Cancer Res 2000, 2:32-44.
21. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25:581-611.
22. Donegan S.E., Naples K.M. Epidermal growth factor receptor inhibitors: a novel anticancer therapy. Cancer Pract 2002, 10:53-56.
23. Ng S.S., Tsao M.S., Nicklee T., Hedley D.W. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 2002, 1:777-783.
24. Juang S.H., Wei S.J., Hung Y.M., Hsu C.Y., Yang D.M., Liu K.J., et al. IFN-beta induces caspase-mediated apoptosis by disrupting mitochondria in human advanced stage colon cancer cell lines. J Interferon Cytokine Res 2004, 24:231-243.
25. Johns T.G., Mackay I.R., Callister K.A., Hertzog P.J., Devenish R.J., Linnane A.W. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta. J Natl Cancer Inst 1992, 84:1185-1190.
26. Salmon P., Le Cotonnec J.Y., Galazka A., Abdul-Ahad A., Darragh A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J Interferon Cytokine Res 1996, 16:759-764.
27. Einhorn S., Grander D. Why do so many cancer patients fail to respond to interferon therapy?. J Interferon Cytokine Res 1996, 16:275-281.
28. Buchwalder P.A., Buclin T., Trinchard I., Munafo A., Biollaz J. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res 2000, 20:857-866.
29. Cho P.S., Messina D.J., Hirsh E.L., Chi N., Goldman S.N., Lo D.P., et al. Immunogenicity of umbilical cord tissue derived cells. Blood 2008, 111:430-438.
30. Weiss M.L., Anderson C., Medicetty S., Seshareddy K.B., Weiss R.J., Vanderwerff I., et al. Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells 2008.
31. Nakamura K., Ito Y., Kawano Y., Kurozumi K., Kobune M., Tsuda H., et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther 2004, 11:1155-1164.
32. Azizi S.A., Stokes D., Augelli B.J., DiGirolamo C., Prockop D.J. Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats-similarities to astrocyte grafts. Proc Natl Acad Sci USA 1998, 95:3908-3913.
33. Kopen G.C., Prockop D.J., Phinney D.G. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci USA 1999, 96:10711-10716.
34. Weiss M.L., Medicetty S., Bledsoe A.R., Rachakatla R.S., Choi M., Merchav S., et al. Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells 2006, 24:781-792.
35. Ayuzawa A., Doi C., Rachakatla R.S., Pyle M.M., Maurya D.K., Troyer D., et al. Naïve human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo. Cancer Lett 2009, 280:31-37.
36. Ganta C., Chiyo D., Ayuzawa R., Rachakatla R., Pyle M., Andrews G., et al. Rat umbilical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation. Cancer Res 2009, 69:1815-1820.
37. Mitchell K.E., Weiss M.L., Mitchell B.M., Martin P., Davis D., Morales L., et al. Matrix cells from Wharton's jelly form neurons and glia. Stem Cells 2003, 21:50-60.
38. Weiss M.L., Troyer D.L. Stem cells in the umbilical cord. Stem Cell Rev 2006, 2:155-162.